Longhi Raffaele, Corbioli Silvia, Fontana Stefano, Vinco Federicia, Braggio Simone, Helmdach Lydia, Schiller Jürgen, Boriss Hinnerk
GlaxoSmithKline Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy.
Drug Metab Dispos. 2011 Feb;39(2):312-21. doi: 10.1124/dmd.110.036095. Epub 2010 Nov 11.
Estimating the unbound fraction of drugs in brain has become essential for the evaluation and interpretation of the pharmacokinetics and pharmacodynamics of new central nervous system drug candidates. Dialysis-based methods are considered to be accurate for estimating the fraction unbound in brain; however, these techniques are hampered by a low throughput. In this study, we present a novel, matrix-free, high-throughput method for estimating the unbound fraction, based on a sample pooling approach combining the TRANSIL brain absorption assay with liquid chromatography-mass spectrometry. The base measurement of the TRANSIL approach is the affinity to brain membranes, and this method is used directly to predict the free fraction in brain. The method was evaluated by comparing the free fraction of drugs in brain [f(u,brain) (%)] obtained using the TRANSIL brain absorption assay and equilibrium dialysis methods for a test set of 65 drugs (27 marketed and 38 proprietary drugs). A good correlation (r(2) > 0.93) of f(u,brain) (%) between the TRANSIL brain absorption assay and equilibrium dialysis was observed. Moreover, we compared the lipid composition of rat and porcine brain and analyzed the influence of the brain albumin content on brain tissue binding measurement. The comparison of the lipid composition indicated only minor differences between rat and porcine brain, and albumin appears to have a low impact on brain tissue binding measurements. The TRANSIL brain absorption assay with sample pooling methodology not only significantly reduces the biological matrix required but also increases the throughput, compared with the conventional dialysis methods.
估算脑内药物的游离分数对于评估和解释新型中枢神经系统候选药物的药代动力学和药效学至关重要。基于透析的方法被认为在估算脑内游离分数方面较为准确;然而,这些技术存在通量低的问题。在本研究中,我们提出了一种基于样品合并方法的新型、无基质、高通量估算游离分数的方法,该方法将TRANSIL脑吸收测定与液相色谱 - 质谱联用。TRANSIL方法的基本测量是对脑膜的亲和力,并且该方法直接用于预测脑内的游离分数。通过比较使用TRANSIL脑吸收测定和平衡透析方法获得的65种药物(27种上市药物和38种专利药物)测试集的脑内药物游离分数[f(u,brain)(%)],对该方法进行了评估。观察到TRANSIL脑吸收测定和平衡透析之间的f(u,brain)(%)具有良好的相关性(r(2)>0.93)。此外,我们比较了大鼠和猪脑的脂质组成,并分析了脑白蛋白含量对脑组织结合测量的影响。脂质组成的比较表明大鼠和猪脑之间只有微小差异,并且白蛋白似乎对脑组织结合测量影响较小。与传统透析方法相比,采用样品合并方法的TRANSIL脑吸收测定不仅显著减少了所需的生物基质,还提高了通量。